Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 16;79(6):1031-1034.
doi: 10.1292/jvms.17-0018. Epub 2017 May 1.

Long term effects of cilostazol in a dog with sick sinus syndrome

Nobuyuki Kanno  1 , Tomohiro Suzuki  2
Affiliations
Case Reports

Long term effects of cilostazol in a dog with sick sinus syndrome

Nobuyuki Kanno et al. J Vet Med Sci. .

Abstract

Sick sinus syndrome (SSS) is a type of bradyarrhythmia that can lead to syncope. Cilostazol has been reported to be an effective treatment for human patients with SSS and other bradyarrhythmias. This report describes the successful long-term treatment with cilostazol in a dog with SSS. A nine-year old intact male Miniature Schnauzer presented with a history of syncopal episodes and unsteady gait. After cilostazol treatment, the total heart rate (HR), mean HR, and frequency of premature ventricular contractions (PVCs) increased, while the maximum HR and maximum pause time decreased. Additionally, the number of syncopal episodes decreased. The dog died suddenly, 1,418 days after the start of cilostazol treatment. Cilostazol may be a useful therapeutic agent in canines with SSS.

Keywords: cilostazol; dog; sick sinus syndrome.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The electrocardiogram recording (lead II; 50 mm/sec), obtained from a dog with sick sinus syndrome, showing sinus arrest before treatment with cilostazol.
Fig. 2.
Fig. 2.
Number of syncopal episodes recorded by the owner, per day, before and after treatment.
See this image and copyright information in PMC

References

    1. Akiyama H., Kudo S., Shimizu T.1985. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 357A: 1124–1132. - PubMed
    1. Atarashi H., Endoh Y., Saitoh H., Kishida H., Hayakawa H.1998. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J. Cardiovasc. Pharmacol. 31: 534–539. doi: 10.1097/00005344-199804000-00010 - DOI - PubMed
    1. Ebisawa T., Ohta Y., Funayama M., Yamano S., Mizuno M., Mizuno T., Kasuya A., Sawada T., Lee J., Mizukoshi T., Uechi M.2013. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs. Res. Vet. Sci. 94: 717–721. doi: 10.1016/j.rvsc.2012.12.007 - DOI - PubMed
    1. Johnson M. S., Martin M. W., Henley W.2007. Results of pacemaker implantation in 104 dogs. J. Small Anim. Pract. 48: 4–11. doi: 10.1111/j.1748-5827.2006.00190.x - DOI - PubMed
    1. Kato R.2006. Efficacy of PDE III inhibitor cilostazol in sick sinus syndrome. Jpn. J. Clin. Exp. Med. 83: 1383–1387 (in Japanese).

Publication types